CN105395591A - Boraginaceae cynoglossum plant and new application of extractive thereof - Google Patents
Boraginaceae cynoglossum plant and new application of extractive thereof Download PDFInfo
- Publication number
- CN105395591A CN105395591A CN201510894505.1A CN201510894505A CN105395591A CN 105395591 A CN105395591 A CN 105395591A CN 201510894505 A CN201510894505 A CN 201510894505A CN 105395591 A CN105395591 A CN 105395591A
- Authority
- CN
- China
- Prior art keywords
- family plant
- borage family
- lindelofia stylosa
- extraction
- lindelofia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of medicine, and relates to a boraginaceae cynoglossum plant and new application of extractive thereof, in particular to the Boraginaceae cynoglossum plant and the application of the extractive of the Boraginaceae cynoglossum plant in preparation of medicine treating fundus maculopathy, wherein fundus maculopathy includes central exudative chorioretinopathy, central serous chorioretinopathy, senile macular degeneration, diabetic fundus macular degeneration, hypertensive macular degeneration and the like. Preparations prepared from the boraginaceae cynoglossum plant and the extractive of the boraginaceae cynoglossum plant serving as active ingredients have remarkable curative effects on fundus maculopathy and are safe and free of side effects. The boraginaceae cynoglossum plant belongs to a natural medicinal material and is wide in source, so that a novel choice is provided for treating the diseases clinically.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to the novelty teabag of Lindelofia stylosa as one borage family plant and extract thereof.
Background technology
Optical fundus is by the macula area on retina, optical fundus blood vessel, papilla of optic nerve, optic nerve fiber, retina, and the formation such as postretinal choroid, and the pathological changes at these positions is referred to as retinopathy." macula lutea " is a normal physiological region on eye ground, is positioned at foveal region of retina, concentrates a large amount of visual function cell, can identify most of optical signallings such as shape, size, color, depth, distance, is the significant points determining visual function.
Fundus flavimaculatus pathological changes be a kind of in, the common disease affecting macula lutea of old people, be in a kind of grievous injury, the commonly encountered diseases of old people's vision, with visual deterioration, there is central scotoma, metamorphopsia is cardinal symptom, severe patient can blinding, and in giving, the life of old people and physical and mental health cause great puzzlement.Retinopathy mainly comprises: central serous chorioretinopathy, features of central exudative chorioretinopathy, age-related macular degeneration, CLBSflCAL OBSERVATION, hypertensive cerebral maculopathy etc.
Current doctor trained in Western medicine mainly takes the physical therapy treatment such as laser and light power (PDT) to fundus flavimaculatus pathological changes, and the therapy such as intraocular injection anti-vascular endothelial growth factor (VEGF) class biological preparation medicine.
1, laser therapy: the heat energy produced with laser, destroys the aberrant nascent vessels of macular area.The principal risk of this therapy is, laser is slightly excessive, impels choroidal neovascularization hypertrophy on the contrary, and also produces damage to neighbouring normal structure, makes visual function be subject to larger infringement.
2, photodynamic therapy (PDT): be that a species specific photosensitizer is expelled in the blood of patient, when drug cycles is to retina, irradiate with 689nm laser and excite photosensitizer, thus destroy abnormal new vessels, and normal retinal tissue is not damaged.This therapy treats at present moist fundus flavimaculatus pathological changes the most frequently used and safety and effective Therapeutic Method in the world.
3, anti-vascular endothelial growth factor (VEGF) class biological products assay institute: anti-vascular endothelial growth factor (VEGF) class biological products assay institute is the treatment being mainly used in wet age related macular degeneration (wAMD) in recent years carried out in the world.Anti-vascular endothelial growth factor (VEGF) class biological preparation medicine comprises Lucentis, A Wasiting and domestic Kang Boxipu etc.This therapy is by this type of drug injection in ophthalmic vitreous chamber, suppresses the angiogenic growth of ophthalmic, to reach the object of symptom management development.
Laser therapy and photodynamic therapy, only can close the new vessels existed, and can not stop the formation of new new vessels, is therefore a kind of symptomatic treatment.These therapies not only somewhat expensive, and often need repeatedly to execute art depending on the state of an illness, be high financial burden to patient.There is multiple deficiency or defect in anti-vascular endothelial growth factor (VEGF) class biological products assay institute: 1) can only develop by symptom management, can not change the pathological lesion caused.2) curative effect is unstable, and clinical expection is undesirable, and rate is high repeatedly, and there is certain untoward reaction and risk.Fade after the course by the phase for the curative effect of such as Lucentis, the later stage of life-time service anti-vascular endothelial growth factor (VEGF) preparation for treating, has potential blind risk etc.3) somewhat expensive, a thousands of unit of pin is to unit up to ten thousand, and domestic General Requirements injects three pins, and according to U.S. Patent specification, and three months monthly pins, after this in the middle of 3 years, should at least inject seven, eight times every year.If code requirement like this, medical expense is up to hundreds thousand of unit, and this therapy injection belongs to medicine at one's own expense at home, and expense high is like this difficult to bear to most patient.And doctor EliasReichel more points out: " neovascular eye diseases often needs continuously, life-long therapy to be to reach best curative effect." then medical expense is huger.
Boraginaceae Cynoglossum (or make Herba Carpesii Cernui belong to, but its Latin generic name is Cynoglossum) plant, according to data introductions such as " Chinese Plants will ", about 28 kinds in the whole world, there is kind more than ten in China.Lindelofia stylosa as one borage family plant plesiomorphism, effect is close, and wherein distribute the widest, most representative plant is Fructus Lithospermi Zollingeri, Herba Cynoglossi lanceolati and Herba Carpesii Cernui.
Carry according to " national Chinese herbal medicine compilation ": Fructus Lithospermi Zollingeri Cynoglossumzeylanicum (Vahl) Thunb.exLehm., annual herb, among the people be commonly called as paste that bone is loose, Radix Clematidis Clarkeanae, sticky stickweed, sticky goddess, pigtail, large Fructus Lithospermi Zollingeri.The micro-hardship of Fructus Lithospermi Zollingeri, cold; Clearing away heat-damp and promoting diuresis, promoting blood flow to regulate menstruation.Cure mainly hepatitis, menoxenia, leucorrhea, edema.External is usually used in treatment furuncle carbuncle, venom, traumatic injury, fracture.Herba Cynoglossi lanceolati CynoglossumlanceolatumForsk., is used as medicine with herb, root.Heat-clearing and toxic substances removing, inducing diuresis to remove edema, invigorates blood circulation.Cure mainly acute nephritis, menoxenia; Carbuncle sore tumefacting virus is controlled in external, venom.Herba Carpesii Cernui CynoglossumamabileStapfetDrumm. perennial herb, be among the peoplely commonly called as blue cloth skirt, Radix Cynoglossi Amabillis (Herba Cynoglossi Amabilis), bullshit Radix Raphani, bullshit indigo plant flower, paste that bone is loose, large fertile root, Radix Clematidis Clarkeanae, JIZHUASHEN, tackle all problems at once, LVHUA leaf, the LVHUA heart, seven-star arrow [Chongqing], Radix Wahlenbergiae Marginatae [Honghe, Yunnan] etc.Herba Carpesii Cernui is sweet, bitter, cool, clearing away heat-damp and promoting diuresis, and dissipating blood stasis stops blooding, cough-relieving.For malaria, hepatitis, dysentery, dysurea, leucorrhea, pulmonary tuberculosis is coughed; Wound hemorrhage is controlled in external, fracture, stremma.
Lindelofia stylosa as one borage family plant form is very close, and more difficult their difference is come, the dry product particularly purchased.When purchasing medical material dry product from the masses, no matter being purchase Fructus Lithospermi Zollingeri, Herba Cynoglossi lanceolati or purchase Herba Carpesii Cernui, is all based on the mixture of the Lindelofia stylosa as one borage family plant of Fructus Lithospermi Zollingeri, Herba Cynoglossi lanceolati and Herba Carpesii Cernui substantially.Therefore in embodiment, Lindelofia stylosa as one borage family plant used is the dry products of at least two kinds of mixing in Fructus Lithospermi Zollingeri, Herba Cynoglossi lanceolati and the Herba Carpesii Cernui purchased in market, referred to as Lindelofia stylosa as one borage family plant in the present invention.
Not about independent be the relevant report that raw material and the pharmaceutical composition containing Lindelofia stylosa as one borage family plant are applied to treatment fundus flavimaculatus pathological changes with Lindelofia stylosa as one borage family plant.
Summary of the invention
First technical problem solved by the invention is to provide the novelty teabag of Lindelofia stylosa as one borage family plant and extract thereof.
Concrete, the present invention is to provide Lindelofia stylosa as one borage family plant and the purposes of extract in the medicine of preparation treatment fundus flavimaculatus pathological changes thereof.
In technique scheme, described fundus flavimaculatus pathological changes is: features of central exudative chorioretinopathy, central serous chorioretinopathy, age-related macular degeneration, diabetic fundus macular degeneration, hypertensive cerebral fundus macular degeneration etc.
In technique scheme, Lindelofia stylosa as one borage family plant adopts the herb of at least one in Fructus Lithospermi Zollingeri, Herba Cynoglossi lanceolati, Herba Carpesii Cernui or other Cynoglossum plants.Its primary crude drug, processed product or extract can be used.
In technique scheme, described extract is water or extractive with organic solvent, or adopts carbon dioxide supercritical extraction method to prepare extract obtained.
Wherein, described organic solvent is the solvent of the opposed polarity such as ethanol, methanol.
Second technical problem solved by the invention is to provide a kind of pharmaceutical composition for the treatment of fundus flavimaculatus pathological changes.
Pharmaceutical composition of the present invention be with the primary crude drug of the Lindelofia stylosa as one borage family plant of effective dose, processed product or extract for active component, add the medicament that customary adjuvant is pharmaceutically prepared from.
Pharmaceutical composition of the present invention be with the primary crude drug of the Lindelofia stylosa as one borage family plant of effective dose, processed product or extract for active component, add the various compound preparations that pharmaceutically acceptable Chinese medicine or chemicals are prepared into.
In technique scheme, described medicament is oral formulations, external preparation or ejection preparation.
The medicine of above-mentioned various dosage form all can be prepared according to the conventional method of pharmaceutical field.3rd technical problem solved by the invention is to provide the preparation method of the pharmaceutical composition of above-mentioned treatment fundus flavimaculatus pathological changes.Comprise:
Method one: Lindelofia stylosa as one borage family plant is ground into fine powder, mixing powder; Or
Method two: Lindelofia stylosa as one borage family plant is ground into fine powder, encapsulated capsule; Or
Method three: Lindelofia stylosa as one borage family plant is ground into fine powder, tabletting tablet; Or
Method four: after Lindelofia stylosa as one borage family plant water boiling and extraction, filters to obtain decoction liquor; Or
Method five: after Lindelofia stylosa as one borage family plant water boiling and extraction, filters to obtain decoction liquor, dry decoction liquor; Or
Method six: after Lindelofia stylosa as one borage family plant water boiling and extraction, concentrated extracting solution makes granule, granule; Or
Method seven: after Lindelofia stylosa as one borage family plant water boiling and extraction, concentrated extracting solution makes granule, encapsulated capsule; Or
Method eight: after Lindelofia stylosa as one borage family plant water boiling and extraction, concentrated extracting solution makes granule, tabletting tablet; Or
Method nine: after Lindelofia stylosa as one borage family plant water boiling and extraction, make water decoction, or add customary adjuvant and make oral liquid, syrup, mixture; Or
Method ten: after Lindelofia stylosa as one borage family plant water boiling and extraction, concentrated extracting solution, adds the organic solvents such as ethanol, through repeatedly dissolving, precipitating, filter, concentrated filtrate, adds customary adjuvant and makes oral liquid, syrup, mixture; Or
Method 11: after Lindelofia stylosa as one borage family plant water boiling and extraction, concentrated extracting solution, adds the organic solvents such as ethanol, and through repeatedly dissolving, precipitating, filter, concentrated, dried filtrate, adds customary adjuvant and make tablet, capsule, granule; Or
Method 12: after Lindelofia stylosa as one borage family plant water boiling and extraction, concentrated extracting solution, adds the organic solvents such as ethanol, through repeatedly dissolving, precipitating, filter, concentrated filtrate, add water for injection and customary adjuvant, adjust about pH to 7, make injection through sterilizing; Or
Method 13: after Lindelofia stylosa as one borage family plant water boiling and extraction, concentrated extracting solution, adds the organic solvents such as ethanol, through repeatedly dissolving, precipitating, filter, concentrated filtrate, add water for injection and customary adjuvant, adjust about PH to 7, make eye drop through sterilizing.
The Drug therapy fundus flavimaculatus pathological changes that inventor prepares with Lindelofia stylosa as one borage family plant and extract thereof, curative effect is certain, stable, for this kind of disease of clinical treatment provides new selection.
Obviously, according to foregoing of the present invention, according to ordinary technical knowledge and the customary means of this area, not departing under the present invention's above-mentioned basic fundamental thought prerequisite, the amendment of other various ways, replacement or change can also be made.
The detailed description of the invention of form by the following examples, is described in further detail foregoing of the present invention again.But this should be interpreted as that the scope of the above-mentioned theme of the present invention is only limitted to following example.All technology realized based on foregoing of the present invention all belong to scope of the present invention.
Detailed description of the invention
The present invention adopts Lindelofia stylosa as one borage family plant or its extract purposes in the medicine of preparation treatment fundus flavimaculatus pathological changes.
Lindelofia stylosa as one borage family plant used is the herb of Lindelofia stylosa as one borage family plant, as herb, the herb of Herba Cynoglossi lanceolati CynoglossumlanceolatumForsk., the herb of Herba Carpesii Cernui CynoglossumamabileStapfetDrumm. of Fructus Lithospermi Zollingeri Cynoglossumzeylanicum (Vahl) Thunb.exLehm., or the herb of other Lindelofia stylosa as one borage family plant, can be the wherein kind of plant in Cynoglossum plants, also can be their any mixture.Lindelofia stylosa as one borage family plant form is very close, and more difficult their difference is come, the dry product particularly purchased.When purchasing medical material dry product from the masses, no matter being purchase Fructus Lithospermi Zollingeri, Herba Cynoglossi lanceolati or purchase Herba Carpesii Cernui, is all based on the mixture of the Lindelofia stylosa as one borage family plant of Fructus Lithospermi Zollingeri, Herba Cynoglossi lanceolati and Herba Carpesii Cernui substantially.Therefore in embodiment, Lindelofia stylosa as one borage family plant used is the dry products of at least two kinds of mixing in Fructus Lithospermi Zollingeri, Herba Cynoglossi lanceolati and the Herba Carpesii Cernui purchased in market, is called for short Lindelofia stylosa as one borage family plant in embodiment.
Conveniently patient takes, can by Lindelofia stylosa as one borage family plant and extract thereof, then the customary adjuvant added pharmaceutically is prepared into various medicament.
Described medicament is oral formulations, external preparation or ejection preparation.
Further, described oral formulations is decoct, powder, bag tea agent, tablet, tincture, pill, extractum, oral liquid, capsule or granule.Described external preparation is eye ointment or eye drop.
Containing Lindelofia stylosa as one borage family plant primary crude drug in every preparation unit in medicament is 5 ~ 30 grams; Extract is 0.2 ~ 5 gram.Described preparation unit refers to unit taking dose, sheet as every in tablet, capsule every, the every 10ml of oral liquid etc., and said preparation unit is the direct reflection of people's taking dose.
Use fresh goods or the dry product of the Lindelofia stylosa as one borage family plant of purchase in the embodiment of the present invention, be all called Lindelofia stylosa as one borage family plant.
The preparation of embodiment 1 Tablets
Get Lindelofia stylosa as one borage family plant 500 grams, soak 1 hour by 15 times of dose, put Decocting pot and endure 1 hour, leach medicinal liquid, then add 10 times of decoctings 1 hour, leach medicinal liquid, merge twice medicinal liquid, dehydration is concentrated into paste, adds 20% soluble starch dextrin (or adding isodose 200 order crude drug powder), mixing, 60 DEG C of oven dry, pulverize, add 1% magnesium stearate mixing, cross 20 mesh sieve granulate, tabletting, sheet weighs 0.5 gram.Instructions of taking: each 2 ~ 3, three times on the one.
The preparation of embodiment 2 medicinal tea of the present invention
1) get Lindelofia stylosa as one borage family plant 1 kilogram, jointly pulverize, cross 60 ~ 100 mesh sieves, on bag tea machine, pack into teabag with filter paper by every bag 4 grams.Instructions of taking: every day three times, each 2-3 bag, puts into thermos cup by medicated bag at every turn, drinks, after this can continue water 1-2 time with after boiled water vexed bubble 2 hours.This teabag glycol is good to eat, can drink throughout the year.
2) get Lindelofia stylosa as one borage family plant 500 grams, soak 1 hour by 10 times of dose, put Decocting pot and endure 1 hour, leach medicinal liquid, add 10 times of decoctings 1 hour again, leach medicinal liquid, merge twice medicinal liquid, dehydration is concentrated into paste, add dextrin, dry, pulverize at 60 DEG C, granulate, restrain into granule by every packed dose 4.Instructions of taking: 2-3 time on the one: each 1 bag.
The preparation of embodiment 3 water decoction of the present invention
Get Lindelofia stylosa as one borage family plant 30-50 gram, add water about 10 times, soak 1 hour, insert Decocting pot, water decocts 30 minutes after opening, and pours out medicinal liquid, then adds 10 times of water, decocts 30 minutes, merges twice decocting liquid, and early, middle and late point takes for three times.
The preparation of embodiment 4 capsule of the present invention
Get Lindelofia stylosa as one borage family plant 500 grams, soak 1 hour by 10 times of dose, put Decocting pot and endure 1 hour, leach medicinal liquid, add 10 times of decoctings 1 hour again, leach medicinal liquid, merge twice medicinal liquid, dehydration is concentrated into paste, add 20%200 order crude drug powder, dry, pulverize at 60 DEG C.This medicated powder is restrained into capsule by every explosive payload 0.3.Instructions of taking: each 3-4 grain, three times on the one.
The preparation of embodiment 5 oral liquid of the present invention
Get Lindelofia stylosa as one borage family plant 500 grams, soak 1 hour by 10 times of dose, put Decocting pot and endure 1 hour, leach medicinal liquid, add 10 times of decoctings 1 hour again, leach medicinal liquid, merge twice medicinal liquid, after fine straining, dehydration is concentrated into density d=1.2-1.3 (70 ~ 80 DEG C of surveys),, add suitable antiseptic and correctives, be sub-packed in 10ml glass bottle, sealing, steam sterilization.Usage: oral, one time 1-2 props up, every day three times.
The preparation of embodiment 6 injection of the present invention
Get Lindelofia stylosa as one borage family plant 2 kilograms, adding distil water 10 times, boils 1 hour, filter, residue adds 10 times of decocting in water 1 hour again, filters, merging filtrate, is concentrated into paste, adds the ethanol of 96%, precipitation process three times, containing amount of alcohol in solution is for the first time 60%, and second time is 70%, third time is 80%, all places 24h, sucking filtration at every turn, reclaim ethanol, by filtrate adding distil water to 800 milliliter.Add the active carbon of 1%, sucking filtration, filtrate adding distil water to 1000 milliliter, be heated to 80 DEG C, add 2% benzyl alcohol, sucking filtration is to clear and bright repeatedly, in embedding 2 milliliters of ampoules, and steam sterilization 30 minutes, for subsequent use.Intramuscular injection, three times on the one, each 4 milliliters.
The preparation of embodiment 7 mixture of the present invention
Fructus Lithospermi Zollingeri 30g Radix Astragali 20g Radix Salviae Miltiorrhizae 15g Fructus Lycii 20g Radix Puerariae 15g Flos Lonicerae 20g Semen Cassiae 15g Fructus Leonuri 15g, decocting in water 2 times, merges twice medicinal liquid, and a bu 3 times is taken.
Originally by the method for embodiment 1,2,4,5, tablet, capsule, granule and oral liquid can be made respectively.
The preparation of embodiment 8 eye drop of the present invention
Get Lindelofia stylosa as one borage family plant 2 kilograms, adding distil water 10 times, boils 1 hour, filter, residue adds 10 times of decocting in water 1 hour again, filters, merging filtrate, is concentrated into paste, adds the ethanol of 96%, precipitation process three times, containing amount of alcohol in solution is for the first time 60%, and second time is 70%, third time is 80%, all places 24h, sucking filtration at every turn, reclaim ethanol, by filtrate adding distil water to 800 milliliter.Add the active carbon of 1%, sucking filtration, filtrate adding distil water to 1000 milliliter, be heated to 80 DEG C, add 2% benzyl alcohol, sucking filtration is to clear and bright repeatedly, adds the adjuvants such as disodium edetate, sodium ascorbate, methyl hydroxybenzoate, and embedding is bottled, and steam sterilization is for subsequent use.
The preparation that inventor is active fraction preparation with Lindelofia stylosa as one borage family plant and extract thereof, is used for the treatment of the patient of fundus flavimaculatus pathological changes, totally 32 example 34.All test eyesight before all patient treatments, intraocular pressure, slit lamp microscope, fluorescence fundus angiography (FFA) and optical coherence tomography (OCT) etc., according to the different state of an illness, general medication 1-6 month, respectively at latter 2 months for the treatment of, 3 months and 6 months checking eyesights, intraocular pressure and eye ground.Result: after treatment, accounts for 76.47% by effective 26, effective 6, accounts for 17.64%, invalid 2, accounts for 5.88%, and total effective rate is 94.12%.Conclusion: Lindelofia stylosa as one borage family plant and extract thereof are that the preparation of active fraction preparation is evident in efficacy to fundus flavimaculatus pathological changes, can effectively develop by symptom management, disappearing of effective promotion retinal edema, the absorption of promote retinal hemorrhage, oozing out, vision improves and improves, and metamorphopsia is corrected substantially.
Clinical case:
1, man, 72 years old, retired professor.Right eye before 7 years through hospital diagnosis be dryness fundus flavimaculatus pathological changes, the invalid rear abandoning cure of medication treatment.In February, 2015 goes to a doctor, and center stain almost occupies whole optic disc, and eyesight testing is 0.Take granule of the present invention (method 2 by embodiment 2) preparation in February, 2015) and eye drop (preparing by embodiment 8) 4 months, readme center stain is a fritter mist only, can see the object outside more than ten meter, eyesight testing 0.12.
2, man, 67 years old, retired cadre.Because vision sharply declines, metamorphopsia is medical in April, 2014 to West China Hospital.Visual acuity chart is detected as 0.12, through multiple inspections such as tomoscan, optical fundus radiographies, is diagnosed as: right eye macular region hemorrhage, edema, right eye PCV (choroid polypoid lesion).Doctor advised makes light powered surgical ten Lucentis injection for curing, after consulting associated specialist, do not adopt this therapy.After take Fructus Lithospermi Zollingeri granule (method 2 by embodiment 2) preparation) treatment, take three months, through check, retinal hemorrhage absorbs completely, edema disappear, focus stablize, display the state of an illness be effectively controlled, vision is recovered to some extent.Continue to take 6 months, metamorphopsia is eliminated substantially, and vision detects 0.2, and center bulk black speck originally becomes a fritter mist, and overall vision obtains part and recovers and improve.
3, female, 43 years old, through Sichuan Province's examination in hospital, makes a definite diagnosis the exudative chorioretinopathy of property centered by left eye, and bear huge medical care expenses and change because of unable the treatment that takes traditional Chinese medicine, the several months has no result, and vision declines rapidly.After change take Fructus Lithospermi Zollingeri granule (method 2 by embodiment 2) preparation) 4 months, through check, macular region hemorrhage, edema disappear, vision reaches 0.25, and metamorphopsia is corrected substantially.
4, female, 63 years old, suffers from hypertension.Because blurred vision is gone to a doctor before 2 years, through looking into, left vision 0.15, fundus flavimaculatus district new vessels is hemorrhage, and edema is diagnosed as hypertensive cerebral choroidal neovascular maculopathy, and through monthly injecting 3 pin Lucentis treatments, the state of an illness is controlled.Disease relapse after half a year, then changes and takes Fructus Lithospermi Zollingeri granule (method 2 by embodiment 2) preparation) treatment, take after 6 months and check, macular area old focus is stablized, and without hemorrhage, edema, eyesight testing is 0.3, and metamorphopsia is corrected.
5, man, 57 years old, diabetics, main suit's blurred vision, have shadow to wave at the moment, metamorphopsia etc.Through looking into, left vision 0.3, right vision 0.15, retina of right eye edema, new vessels is hemorrhage, vitreous opacity, is diagnosed as diabetic maculopathy.Through taking Fructus Lithospermi Zollingeri mixture (preparing by embodiment 7) and eye drop (preparing by embodiment 8) three wheat harvesting periods, through check, left vision 0.4, right vision 0.25, edema and hemorrhagely to absorb completely, shadow and metamorphopsia are eliminated substantially.
Above-mentioned clinical case directly reflects Lindelofia stylosa as one borage family plant and extract is the preparation of active fraction preparation, has significant curative effect to fundus flavimaculatus pathological changes, and safety, has no side effect.And owing to belonging to crude drug, wide material sources, for this disease of clinical treatment provides new selection.
Claims (10)
1. Lindelofia stylosa as one borage family plant and extract thereof the purposes in the medicine of preparation treatment fundus flavimaculatus pathological changes.
2. purposes according to claim 1, it is characterized in that: the exudative chorioretinopathy of property centered by described fundus flavimaculatus pathological changes, central serous chorioretinopathy, age-related macular degeneration, diabetic fundus macular degeneration, hypertensive cerebral fundus macular degeneration.
3. purposes according to claim 1, is characterized in that: described Lindelofia stylosa as one borage family plant adopts the herb of at least one in Fructus Lithospermi Zollingeri, Herba Cynoglossi lanceolati, Herba Carpesii Cernui or other Cynoglossum plants.
4. purposes according to claim 1, is characterized in that: described extract is water or extractive with organic solvent, or adopts carbon dioxide supercritical extraction method to prepare extract obtained.
5. purposes according to claim 4, is characterized in that: described organic solvent is ethanol, methanol.
6. treat the pharmaceutical composition of fundus flavimaculatus pathological changes, it is characterized in that: with the primary crude drug of the Lindelofia stylosa as one borage family plant of effective dose, processed product or extract for active component, add the medicament that customary adjuvant is pharmaceutically prepared from.
7. treat the pharmaceutical composition of fundus flavimaculatus pathological changes, it is characterized in that: with the primary crude drug of the Lindelofia stylosa as one borage family plant of effective dose, processed product or extract for active component, add the medicament that other Chinese medicine pharmaceutically or chemicals are prepared from.
8. the pharmaceutical composition of the treatment fundus flavimaculatus pathological changes according to claim 6,7, is characterized in that: described medicament is oral formulations, external preparation or ejection preparation.
9. the pharmaceutical composition for the treatment of fundus flavimaculatus pathological changes according to claim 8, is characterized in that: described oral formulations is decoct, powder, bag tea agent, tablet, tincture, pill, extractum, oral liquid, capsule or granule; Described external preparation is eye ointment or eye drop.
10. the preparation method of the pharmaceutical composition for the treatment of fundus flavimaculatus pathological changes according to claim 6, is characterized in that: comprise the steps:
Method one: Lindelofia stylosa as one borage family plant is ground into fine powder, mixing powder; Or
Method two: Lindelofia stylosa as one borage family plant is ground into fine powder, encapsulated capsule; Or
Method three: Lindelofia stylosa as one borage family plant is ground into fine powder, tabletting tablet; Or
Method four: after Lindelofia stylosa as one borage family plant water boiling and extraction, filters to obtain decoction liquor; Or
Method five: after Lindelofia stylosa as one borage family plant water boiling and extraction, filters to obtain decoction liquor, dry decoction liquor; Or
Method six: after Lindelofia stylosa as one borage family plant water boiling and extraction, concentrated extracting solution makes granule, granule; Or
Method seven: after Lindelofia stylosa as one borage family plant water boiling and extraction, concentrated extracting solution makes granule, encapsulated capsule; Or
Method eight: after Lindelofia stylosa as one borage family plant water boiling and extraction, concentrated extracting solution makes granule, tabletting tablet; Or
Method nine: after Lindelofia stylosa as one borage family plant water boiling and extraction, make water decoction, or add customary adjuvant and make oral liquid, syrup, mixture; Or
Method ten: after Lindelofia stylosa as one borage family plant water boiling and extraction, concentrated extracting solution, adds the organic solvents such as ethanol, through repeatedly dissolving, precipitating, filter, concentrated filtrate, adds customary adjuvant and makes oral liquid, syrup, mixture; Or
Method 11: after Lindelofia stylosa as one borage family plant water boiling and extraction, concentrated extracting solution, adds the organic solvents such as ethanol, and through repeatedly dissolving, precipitating, filter, concentrated, dried filtrate, adds customary adjuvant and make tablet, capsule, granule; Or
Method 12: after Lindelofia stylosa as one borage family plant water boiling and extraction, concentrated extracting solution, adds the organic solvents such as ethanol, through repeatedly dissolving, precipitating, filter, concentrated filtrate, add water for injection and customary adjuvant, adjust about pH to 7, make injection through sterilizing; Or
Method 13: after Lindelofia stylosa as one borage family plant water boiling and extraction, concentrated extracting solution, adds the organic solvents such as ethanol, filter through repeatedly dissolving, precipitating, through anion exchanger, concentrated filtrate, adds water for injection and customary adjuvant, adjust about PH to 7, make eye drop through sterilizing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510894505.1A CN105395591A (en) | 2015-12-07 | 2015-12-07 | Boraginaceae cynoglossum plant and new application of extractive thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510894505.1A CN105395591A (en) | 2015-12-07 | 2015-12-07 | Boraginaceae cynoglossum plant and new application of extractive thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105395591A true CN105395591A (en) | 2016-03-16 |
Family
ID=55461588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510894505.1A Pending CN105395591A (en) | 2015-12-07 | 2015-12-07 | Boraginaceae cynoglossum plant and new application of extractive thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105395591A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112675158A (en) * | 2021-01-26 | 2021-04-20 | 苏州市立医院 | Function of shikonin in preparing choroid neovascularization therapeutic medicine |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101112500A (en) * | 2007-08-29 | 2008-01-30 | 北京艺信堂医药研究所 | Chinese traditional medicine composition for treating diabetes retina pathological changes |
| CN101347488A (en) * | 2008-08-11 | 2009-01-21 | 赵明生 | Uses of plants from genera Cynoglossum of family Boraginaceae and extract thereof in preparing medicament for treating respiratory illness |
| CN101390918A (en) * | 2008-08-11 | 2009-03-25 | 赵明生 | New uses of Boraginaceae cynoglossum plant and extract thereof in medicine domain |
| CN101401834A (en) * | 2008-08-11 | 2009-04-08 | 赵明生 | Uses of boraginaceae cynoglossum plant and its extract in preparing medicament for treating diseases such as hyperosteogeny, arthritis |
-
2015
- 2015-12-07 CN CN201510894505.1A patent/CN105395591A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101112500A (en) * | 2007-08-29 | 2008-01-30 | 北京艺信堂医药研究所 | Chinese traditional medicine composition for treating diabetes retina pathological changes |
| CN101347488A (en) * | 2008-08-11 | 2009-01-21 | 赵明生 | Uses of plants from genera Cynoglossum of family Boraginaceae and extract thereof in preparing medicament for treating respiratory illness |
| CN101390918A (en) * | 2008-08-11 | 2009-03-25 | 赵明生 | New uses of Boraginaceae cynoglossum plant and extract thereof in medicine domain |
| CN101401834A (en) * | 2008-08-11 | 2009-04-08 | 赵明生 | Uses of boraginaceae cynoglossum plant and its extract in preparing medicament for treating diseases such as hyperosteogeny, arthritis |
Non-Patent Citations (4)
| Title |
|---|
| 朱丽慧: "眼底黄斑病变的中医症型分析与中药分类治疗", 《中医中药》 * |
| 汪毅等: "《精选草药菜色图谱.3》", 31 May 2014, 贵州科技出版社 * |
| 肖都盼等: "眼底黄斑病变的中医分型分析与中药治疗观察", 《环球中医药》 * |
| 陈虎彪等: "《中草药野外识别图谱》", 31 December 2013, 福建科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112675158A (en) * | 2021-01-26 | 2021-04-20 | 苏州市立医院 | Function of shikonin in preparing choroid neovascularization therapeutic medicine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vats et al. | Anti-cataract activity of Pterocarpus marsupium bark and Trigonella foenum-graecum seeds extract in alloxan diabetic rats | |
| CN104225265B (en) | A kind of Traditional Chinese medicine composition for relieving asthenopia | |
| CN102813780A (en) | Chinese herbal medicinal compound preparation used for treating macular degeneration of old people and preparation method thereof | |
| CN103845418A (en) | Chinese medicinal composition for treating fundus hemorrhage and application thereof | |
| CN104971190A (en) | Application of dioscorea cirrhosa in preparation of medicines for preventing or treating diabetes and complications of diabetes | |
| CN109512870B (en) | Pharmaceutical composition, preparation method and application thereof | |
| CN105395591A (en) | Boraginaceae cynoglossum plant and new application of extractive thereof | |
| CN102258709B (en) | Traditional Chinese medicine preparation for treating diabetic retinopathy, and preparation method thereof | |
| CN109260397A (en) | A kind of Chinese medicine composition for treating Vascular retinopathy | |
| CN104435487A (en) | Traditional Chinese medicine for treating hypertension complicated with diabetic fundi disease and preparation method thereof | |
| CN104306546B (en) | A kind of Chinese medicine composition and its decoction, pill and powder for being used to treat optic atrophy | |
| CN103623139A (en) | Application of traditional Chinese medicine composition to prepare medicaments for treating central serous chorioretinopathy | |
| CN1283477A (en) | 'Yanming' capsules for clearing eyes | |
| CN106540170A (en) | A kind of Chinese medicine for treating the bleeding eye diseases such as macular degeneration, retinal vein obstruction | |
| CN104689079A (en) | Traditional Chinese medicine composition for treating diabetic retinopathy and preparation method thereof | |
| CN104491612A (en) | Purpose of traditional Chinese medicine composition in preparing medicament for treating diabetic retinopathy | |
| CN104306579B (en) | A kind of Chinese medicine for treating deficiency of yin and stagnation of blood diabetic retinopathy and preparation method and application | |
| CN106924655B (en) | Preparation method of traditional Chinese medicine composition for treating age-related macular degeneration | |
| CN104324139B (en) | A kind of pharmaceutical composition treating xerophthalmia | |
| Ansari-Mohseni et al. | Therapeutic effects of herbal medicines in different types of retinopathies: A systematic review | |
| CN106668240A (en) | Pharmaceutical composition for treating vitreous opacity | |
| CN106619816A (en) | Pharmaceutical composition for treating optic atrophy | |
| CN108175818B (en) | Traditional Chinese medicine composition for treating glaucoma and preparation method and application thereof | |
| CN104873668A (en) | Traditional Chinese medicine composition for treating optic atrophy | |
| CN105287863A (en) | Pharmaceutical composition for curing DN (Diabetic Nephropathy) and preparation method of pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160316 |